About this Journal Submit a Manuscript Table of Contents

Transcatheter Aortic Valve Implantation

Call for Papers

Aortic stenosis (AS) is the most frequently encountered valvular heart disease requiring intervention in the adult population, and the consensus is that individuals with severe symptomatic AS and a reasonable life expectancy should be offered aortic valve replacement. AS is Class I recommendation for surgical aortic valve replacement (SAVR). Notably, up to one- third of patients with severe symptomatic AS are not considered for conventional surgical techniques, and this group of patients are known to have a particularly poor prognosis because of comorbidities and frailty.

Since the first-in-man case performed in 2002, transcatheter aortic valve implantation (TAVI) has now been established as an alternative treatment option for patients with severe AS at (very) high operative risk.

Despite growing experience in TAVI, several issues remain including patient selection, stroke, vascular complications, aortic regurgitation, conduction abnormalities, and optimal pharmacological treatment. We invite physicians and researchers dealing with AS to contribute with original research as well as state-of-the-art papers that illustrate and may stimulate continuing efforts to understand the pathophysiology of AS, risk stratification and optimal treatment selection, new transcatheter valve designs, and clinical endpoints related to the high-risk patient populations currently considered for TAVI.

We are particularly interested in papers describing possible abnormalities in the coagulation pathways, conduction disturbances, vascular and bleeding complication, mechanisms and prevalence of cerebrovascular events, and periprosthetic aortic regurgitation following TAVI. Potential topics include, but are not limited to:

  • Pathophysiology of aortic stenosis
  • Abnormalities in the coagulation pathways in AS
  • Recent advances in AS treatment
  • Imaging before/after TAVI procedure
  • Antithrombotic treatment for TAVI and beyond
  • Clinical outcomes following TAVI
  • Vascular and bleeding complication following TAVI
  • Mechanisms, prevalence, and prevention of cerebrovascular events following TAVI
  • Mechanisms, prevalence, and prevention of conduction disturbances following TAVI
  • Mechanisms, prevalence, and prevention of perivalvular aortic regurgitation following TAVI
  • Inflammation versus infection after TAVI
  • Advances in TAVR devices and techniques

Before submission authors should carefully read over the journal’s Author Guidelines, which are located at http://www.hindawi.com/journals/bmri/guidelines/. Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at http://mts.hindawi.com/submit/journals/bmri/vascular.medicine/tavi/ according to the following timetable:

Manuscript DueFriday, 31 January 2014
First Round of ReviewsFriday, 25 April 2014
Publication DateFriday, 20 June 2014

Lead Guest Editor

  • Alaide Chieffo, Interventional Cardiology Unit, San Raffaele Scientific Institute, Milan, Italy

Guest Editors

  • Nicolas Van Mieghem, Interventional Cardiology, Thoraxcenter, Erasmus MC, Rotterdam, The Netherlands
  • Didier Tchetche, Interventional Cardiology Unit, Clinique Pasteur, Toulouse, France